Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

@article{Gao2010ChemicalGS,
  title={Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect},
  author={Min Gao and Richard E. Nettles and Makonen Belema and Lawrence B. Snyder and Van Nhien Albert Nguyen and Robert A. Fridell and Michael H. Serrano-Wu and David R. Langley and Jin-hua Sun and Donald R. O’Boyle and Julie A. Lemm and Chunfu Wang and Jay O. Knipe and Caly Chien and R. J. Colonno and Dennis M. Grasela and Nicholas A Meanwell and Lawrence G. Hamann},
  journal={Nature},
  year={2010},
  volume={465},
  pages={96-100}
}
The worldwide prevalence of chronic hepatitis C virus (HCV) infection is estimated to be approaching 200 million people. Current therapy relies upon a combination of pegylated interferon-α and ribavirin, a poorly tolerated regimen typically associated with less than 50% sustained virological response rate in those infected with genotype 1 virus. The development of direct-acting antiviral agents to treat HCV has focused predominantly on inhibitors of the viral enzymes NS3 protease and the RNA… CONTINUE READING
Highly Influential
This paper has highly influenced 35 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS